{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:47:33Z","timestamp":1792705653085,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T00:00:00Z","timestamp":1479427200000},"content-version":"vor","delay-in-days":201,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1038\/mt.2016.13","type":"journal-article","created":{"date-parts":[[2016,1,12]],"date-time":"2016-01-12T07:20:18Z","timestamp":1452583218000},"page":"937-945","source":"Crossref","is-referenced-by-count":35,"title":["MiR-298 Counteracts Mutant Androgen Receptor Toxicity in Spinal and Bulbar Muscular Atrophy"],"prefix":"10.1016","volume":"24","author":[{"given":"Naemeh","family":"Pourshafie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-lian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G","family":"Harmison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C","family":"Bott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahisa","family":"Katsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Sobue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barrington G","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth H","family":"Fischbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2016.13_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.neuro.23.1.217","article-title":"Glutamine repeats and neurodegeneration","volume":"23","author":"Zoghbi","year":"2000","journal-title":"Annu Rev Neurosci"},{"key":"10.1038\/mt.2016.13_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.gde.2012.01.001","article-title":"Polyglutamine neurodegeneration: expanded glutamines enhance native functions","volume":"22","author":"Orr","year":"2012","journal-title":"Curr Opin Genet Dev"},{"key":"10.1038\/mt.2016.13_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0896-6273(03)00569-5","article-title":"Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport","volume":"40","author":"Szebenyi","year":"2003","journal-title":"Neuron"},{"key":"10.1038\/mt.2016.13_bib4","doi-asserted-by":"crossref","first-page":"12106","DOI":"10.1523\/JNEUROSCI.3032-06.2006","article-title":"Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration","volume":"26","author":"Katsuno","year":"2006","journal-title":"J Neurosci"},{"key":"10.1038\/mt.2016.13_bib5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nn1717","article-title":"JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport","volume":"9","author":"Morfini","year":"2006","journal-title":"Nat Neurosci"},{"key":"10.1038\/mt.2016.13_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/hmg\/ddn310","article-title":"Mitochondrial abnormalities in spinal and bulbar muscular atrophy","volume":"18","author":"Ranganathan","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2016.13_bib7","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/jnr.22011","article-title":"Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease","volume":"87","author":"Yu","year":"2009","journal-title":"J Neurosci Res"},{"key":"10.1038\/mt.2016.13_bib8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature"},{"key":"10.1038\/mt.2016.13_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nrg2504","article-title":"Small silencing RNAs: an expanding universe","volume":"10","author":"Ghildiyal","year":"2009","journal-title":"Nat Rev Genet"},{"key":"10.1038\/mt.2016.13_bib10","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2014.06.005","article-title":"MicroRNAs in cancer: biomarkers, functions and therapy","volume":"20","author":"Hayes","year":"2014","journal-title":"Trends Mol Med"},{"key":"10.1038\/mt.2016.13_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.molcel.2006.07.030","article-title":"MicroRNA pathways modulate polyglutamine-induced neurodegeneration","volume":"24","author":"Bilen","year":"2006","journal-title":"Mol Cell"},{"key":"10.1038\/mt.2016.13_bib12","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/nn.2183","article-title":"miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis","volume":"11","author":"Lee","year":"2008","journal-title":"Nat Neurosci"},{"key":"10.1038\/mt.2016.13_bib13","doi-asserted-by":"crossref","first-page":"14341","DOI":"10.1523\/JNEUROSCI.2390-08.2008","article-title":"The bifunctional microRNA miR-9\/miR-9* regulates REST and CoREST and is downregulated in Huntington's disease","volume":"28","author":"Packer","year":"2008","journal-title":"J Neurosci"},{"key":"10.1038\/mt.2016.13_bib14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature10810","article-title":"The microRNA miR-34 modulates ageing and neurodegeneration in Drosophila","volume":"482","author":"Liu","year":"2012","journal-title":"Nature"},{"key":"10.1038\/mt.2016.13_bib15","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/nm.2791","article-title":"Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2","volume":"18","author":"Miyazaki","year":"2012","journal-title":"Nat Med"},{"key":"10.1038\/mt.2016.13_bib16","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1074\/jbc.M807530200","article-title":"MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1","volume":"284","author":"Boissonneault","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2016.13_bib17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jbi.2011.05.002","article-title":"miRWalk\u2013database: prediction of possible miRNA binding sites by \u201cwalking\u201d the genes of three genomes","volume":"44","author":"Dweep","year":"2011","journal-title":"J Biomed Inform"},{"key":"10.1038\/mt.2016.13_bib18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/nbdi.1997.0126","article-title":"Characterization of an expanded glutamine repeat androgen receptor in a neuronal cell culture system","volume":"3","author":"Brooks","year":"1997","journal-title":"Neurobiol Dis"},{"key":"10.1038\/mt.2016.13_bib19","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.nmd.2014.06.441","article-title":"Early onset and novel features in a spinal and bulbar muscular atrophy patient with a 68 CAG repeat","volume":"24","author":"Grunseich","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1038\/mt.2016.13_bib20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0896-6273(02)00834-6","article-title":"Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy","volume":"35","author":"Katsuno","year":"2002","journal-title":"Neuron"},{"key":"10.1038\/mt.2016.13_bib21","first-page":"Unit 4.17","article-title":"Production of recombinant adeno-associated viral vectors and use in in vitro and in vivo administration","volume":"Chapter 4","author":"Gray","year":"2011","journal-title":"Curr Protoc Neurosci"},{"key":"10.1038\/mt.2016.13_bib22","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1074\/jbc.M609972200","article-title":"Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy","volume":"282","author":"Li","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2016.13_bib23","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2119\/molmed.2012.00271","article-title":"Insulinlike growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy","volume":"18","author":"Rinaldi","year":"2012","journal-title":"Mol Med"},{"key":"10.1038\/mt.2016.13_bib24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/378403a0","article-title":"Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias","volume":"378","author":"Trottier","year":"1995","journal-title":"Nature"},{"key":"10.1038\/mt.2016.13_bib25","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/nature06783","article-title":"LNA-mediated microRNA silencing in non-human primates","volume":"452","author":"Elm\u00e9n","year":"2008","journal-title":"Nature"},{"key":"10.1038\/mt.2016.13_bib26","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/clpt.2012.192","article-title":"Clinical applications for microRNAs in cancer","volume":"93","author":"Nana-Sinkam","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1038\/mt.2016.13_bib27","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/mt.2013.152","article-title":"Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice","volume":"21","author":"Rodr\u00edguez-Lebr\u00f3n","year":"2013","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.13_bib28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.nbd.2013.04.003","article-title":"RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1","volume":"56","author":"Keiser","year":"2013","journal-title":"Neurobiol Dis"},{"key":"10.1038\/mt.2016.13_bib29","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1016\/j.febslet.2014.11.013","article-title":"miR-25 alleviates polyQ-mediated cytotoxicity by silencing ATXN3","volume":"588","author":"Huang","year":"2014","journal-title":"FEBS Lett"},{"key":"10.1038\/mt.2016.13_bib30","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.2353\/ajpath.2009.080718","article-title":"MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus","volume":"174","author":"Maru","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1038\/mt.2016.13_bib31","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/labinvest.2009.12","article-title":"Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues","volume":"89","author":"Hui","year":"2009","journal-title":"Lab Invest"},{"key":"10.1038\/mt.2016.13_bib32","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ijc.26405","article-title":"Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease","volume":"131","author":"Selth","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1038\/mt.2016.13_bib33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1261\/rna.029561.111","article-title":"MicroRNAs 296 and 298 are imprinted and part of the GNAS\/Gnas cluster and miR-296 targets IKBKE and Tmed9","volume":"18","author":"Robson","year":"2012","journal-title":"RNA"},{"key":"10.1038\/mt.2016.13_bib34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1101\/gad.1399806","article-title":"Control of translation and mRNA degradation by miRNAs and siRNAs","volume":"20","author":"Valencia-Sanchez","year":"2006","journal-title":"Genes Dev"},{"key":"10.1038\/mt.2016.13_bib35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fnmol.2014.00050","article-title":"Systemic gene delivery to the central nervous system using Adeno-associated virus","volume":"7","author":"Bourdenx","year":"2014","journal-title":"Front Mol Neurosci"},{"key":"10.1038\/mt.2016.13_bib36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrg2988","article-title":"Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges","volume":"12","author":"Mingozzi","year":"2011","journal-title":"Nat Rev Genet"},{"key":"10.1038\/mt.2016.13_bib37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/humc.2013.087","article-title":"Lessons learned from the clinical development and market authorization of Glybera","volume":"24","author":"Bryant","year":"2013","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1038\/mt.2016.13_bib38","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/mt.2011.98","article-title":"Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.13_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mt.2016.13_bib40","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.13_bib41","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nbt0109-42","article-title":"Crossing the rubicon","volume":"27","author":"Lowenstein","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mt.2016.13_bib42","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nbt0909-804","article-title":"The neonatal blood-brain barrier is functionally effective, and immaturity does not explain differential targeting of AAV9","volume":"27","author":"Saunders","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1038\/mt.2016.13_bib43","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1083\/jcb.200908164","article-title":"Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond","volume":"187","author":"Ilieva","year":"2009","journal-title":"J Cell Biol"},{"key":"10.1038\/mt.2016.13_bib44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.neuron.2014.03.001","article-title":"Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy","volume":"82","author":"Cortes","year":"2014","journal-title":"Neuron"},{"key":"10.1038\/mt.2016.13_bib45","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.celrep.2014.02.008","article-title":"Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy","volume":"7","author":"Lieberman","year":"2014","journal-title":"Cell Rep"},{"key":"10.1038\/mt.2016.13_bib46","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/mt.2011.185","article-title":"Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease","volume":"19","author":"Boudreau","year":"2011","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2016.13_bib47","doi-asserted-by":"crossref","first-page":"9863","DOI":"10.1093\/nar\/gks712","article-title":"Silencing of Parkinson's disease-associated genes with artificial mirtron mimics of miR-1224","volume":"40","author":"Sibley","year":"2012","journal-title":"Nucleic Acids Res"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616302209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616302209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T03:00:08Z","timestamp":1537066808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616302209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S1525001616302209"],"URL":"https:\/\/doi.org\/10.1038\/mt.2016.13","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}